Physician profile
Michael Pinsky
NPI 1164749909
$8,247.32
in general payments reported to CMS, 2019-2025
29 companies · $764 in 2025
The $764 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,230 · 2020: $244 · 2021: $149 · 2022: $713 · 2023: $1,418 · 2024: $728 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,561 · Travel and Lodging: $315 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.75 |
| Travel and Lodging | $314.66 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $2,745.15 | 2019-2020 | |
| Teleflex LLC | $1,302.47 | 2022-2025 | Urolift, Barrigel |
| Cook Medical LLC | $1,229.63 | 2019-2025 | Cook, Fiber Dust, Resonance |
| Cook Incorporated | $677.36 | 2019 | |
| Myriad Genetic Laboratories, INC. | $324.66 | 2022-2023 | Prolaris |
| Astellas Pharma US INC | $294.75 | 2019-2023 | Myrbetriq |
| Calyxo, INC. | $275.63 | 2025 | Cvac Aspiration System |
| Urogen Pharma, INC. | $215.15 | 2022-2025 | Jelmyto |
| Photocure INC | $190.75 | 2022-2025 | Cysview |
| Procept Biorobotics Corporation | $143.34 | 2022-2024 | Aquabeam System |
| Karl Storz Endoscopy-America | $138.05 | 2020 | |
| Sumitomo Pharma America, INC. | $121.83 | 2023-2025 | Gemtesa |
| Intuitive Surgical, INC. | $99.00 | 2019 | |
| Boston Scientific Corporation | $96.92 | 2019 | |
| Hollister Incorporated | $53.13 | 2022-2023 | Infyna Chic |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.43 | 2022-2023 | |
| Ethicon US, LLC | $35.85 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $35.06 | 2025 | Imfinzi |
| Progenics Pharmaceuticals, INC. | $34.02 | 2022 | |
| Endo Pharmaceuticals INC. | $32.37 | 2022 | |
| Merck Sharp & Dohme LLC | $26.92 | 2023 | Keytruda, Lynparza |
| Smith+Nephew, INC. | $19.20 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.51 | 2024 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $17.65 | 2023 | |
| Civco Medical Instruments | $17.64 | 2024 | |
| Olympus America INC. | $16.24 | 2024 | Cysto-Nephro Videoscope |
| C. R. Bard, INC. & Subsidiaries | $13.92 | 2020 | |
| Coloplast Corp | $13.24 | 2021 | |
| Urovant Sciences INC | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.